VENLID: The Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults - Trial NCT06354816
Access comprehensive clinical trial information for NCT06354816 through Pure Global AI's free database. This Phase 4 trial is sponsored by Krankenhaus Barmherzige Schwestern Linz and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Krankenhaus Barmherzige Schwestern Linz
Timeline & Enrollment
Phase 4
May 01, 2024
May 01, 2024
Primary Outcome
To demonstrate a reduction of pain caused by PIVC rated by Numerical Rating Scale (NRS), after application of a 10% lidocaine spray- Separately measured for the plantar side of the hand/vessel at the dorsum manus, and for the forearm/cubita
Summary
Volunteers are invited to undergo 4 insertions of a peripheral intra-venous 18-gauge catheter
 (PIVC); 2 insertions at the the start of the study on the plantar side of the hand/vessel at
 the dorsum manus, 2 insertions after 2-10 hours into the forearm/cubita with and without
 application of a 10-% lidocaine spray (5 hubs of xylocaine 10%-pump spray; AstraZeneca BV,
 Zoetermeer, The Netherlands) prior to the insertion of the PIVC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06354816
Non-Device Trial